A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs MK 8521 (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck
  • Most Recent Events

    • 09 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 24 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 27 May 2014 According to ClinicalTrials.gov record, planned number of patients changed from 48 to 84. An additional cohort of T2DM participants and a cohort of non-diabetic obese participants have been added. Also modified inclusions-exclusion criteria and treatments
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top